Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M. Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder. BMC Psychiatry. 2024 Sep 10;24(1):605. doi: 10.1186/s12888-024-06034-

Hauser RA, Sethi K, Klepitskaya O, Odak S, Joshi N, Kebede N, Olson K, Liang GS, Yonan C, Serbin M. Treatment patterns in a real-world sample of patients with parkinson's disease and motor fluctuations. Poster presented at the 146th 2021 American Neurological Association (ANA) Virtual Meeting; October 17, 2021. [abstract] Ann Neurol. 2021 Oct; 90(S27):S153.

Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Evaluating patients' preferences for Parkinson's disease treatments. Poster presented at the 146th 2021 American Neurological Association (ANA) Virtual Meeting; October 17, 2021. [abstract] Ann Neurol. 2021; 90(S27):S151-2.

Brain C, Kymes S, DiBenedetti DB, Brevig T, Velligan DI. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry. 2018 Aug 13;18(1):253. doi: 10.1186/s12888-018-1833-5

Llorca PM, Lancon C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, Francois C. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 2017 Feb 13;17:67. doi: 10.1186/s12888-017-1213-6

Pujol J, Fenoll R, Forns J, Harrison BJ, Martinez-Vilavella G, Macia D, Alvarez-Pedrerol M, Blanco-Hinojo L, Gonzalez-Ortiz S, Deus J, Sunyer J. Video gaming in school children: how much is enough? Ann Neurol. 2016 Sep;80(3):424-33. doi: 10.1002/ana.24745

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015 Aug 5;15:189. doi: 10.1186/s12888-015-0560-4.

Moragas L, Granero R, Stinchfield R, Fernandez-Aranda F, Froberg F, Aymami N, Gomez-Pena M, Fagundo AB, Islam MA, Del Pino-Gutierrez A, Aguera Z, Savvidou LG, Arcelus J, Witcomb GL, Sauchelli S, Menchon JM, Jimenez-Murcia S. Comparative analysis of distinct phenotypes in gambling disorder based on gambling preferences. BMC Psychiatry. 2015 Apr 15;15:86. doi: 10.1186/s12888-015-0459-0

Shafi MM, Vernet M, Klooster D, Chu CJ, Boric K, Barnard ME, Romatoski K, Westover MB, Christodoulou JA, Gabrieli JDE, Whitfield-Gabrieli S, Pascual-Leone A, Chang BS. Physiological consequences of abnormal connectivity in a developmental epilepsy. Ann Neurol. 2015 Mar;77(3):487-503. doi: 10.1002/ana.24343

Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.

Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.

Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.

Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.

Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.

The Multiple Sclerosis Study Group, Remavich M. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol. 1990 Jun;27(6):591-605. doi: 10.1002/ana.410270603